BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Researchers identified BAG2, MAD2L1, and MDK as novel cancer-driver genes in malignant pleural mesothelioma (MPM). These genes, overexpressed in MPM, represent potential druggable targets for new cancer therapies.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options.
- Identifying novel therapeutic targets is crucial for improving patient prognosis.
- Previous research identified 15 deregulated genes in MPM tissues associated with poor outcomes.
Purpose Of The Study
- To validate previously identified deregulated genes in MPM.
- To determine if these genes function as cancer-drivers in MPM.
- To identify novel druggable targets for MPM treatment.
Main Methods
- Validation of gene expression on an independent MPM patient cohort and cell lines.
- In vitro gene silencing followed by proliferation, cytotoxicity, caspase, and migration assays.
- Immunohistochemistry to assess protein expression in patient tissues.
- Testing of specific inhibitors (Neratinib, iMDK) against identified targets.
Main Results
- BAG2, MAD2L1, and MDK were confirmed as significantly overexpressed and validated as cancer-driver genes in MPM.
- Overexpression of BAG2 and MAD2L1 differentiated MPM from reactive pleural disease (RMP) patients via immunohistochemistry.
- Inhibitors of MAD2L1 (Neratinib) and MDK (iMDK) demonstrated efficacy against MPM cells.
Conclusions
- BAG2, MAD2L1, and MDK are validated cancer-driver genes in malignant pleural mesothelioma.
- These genes represent promising novel druggable targets for MPM therapy.
- Further investigation into BAG2, MAD2L1, and MDK as therapeutic targets is warranted.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...